Emerging drugs for immune thrombocytopenia (ITP)

References

• Godeau B, Provan D, Bussel J. Immune thrombocytopenic purpura in adults. Curr Opin Hematol. 2007;14:535–556.
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113:6511–6521.
   PubMed Web of Science ®Google Scholar
• Salama A. Current treatment options for primary immune thrombocytopenia. Expert Rev Hematol. 2011;4:107–118.
   PubMed Web of Science ®Google Scholar
• Aboud N, Depre F, Salama A. Is autoimmune thrombocytopenia itself the primary disease in the presence of second diseases: data from a long term observation. Transfus Med Hemotherapy. 2016. S. Karger Verlag. 44:23–28.
   PubMed Web of Science ®Google Scholar
• Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol. 2004;25:489–495.
   PubMed Web of Science ®Google Scholar
• Rondina MT, Weyrich AS, Zimmerman GA. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res. 2013;112:1506–1519.
   PubMed Web of Science ®Google Scholar
• Garraud O, Hamzeh-Cognasse H, Pozzetto B, et al. Bench-to-bedside review: platelets and active immune functions - new clues for immunopathology? Crit Care. 2013;17:236.
   PubMed Web of Science ®Google Scholar
• Xu XR, Zhang D, Oswald BE, et al. Platelets are versatile cells: new discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond. Crit Rev Clin Lab Sci. 2016;53:1–22.
   Web of Science ®Google Scholar
• Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010;85:174–180.
   PubMed Web of Science ®Google Scholar
• Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol. 2007;14:515–519.
   PubMed Web of Science ®Google Scholar
• Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur J Haematol Suppl. 2008;124:3308–3315.
   PubMedGoogle Scholar
• Moulis G, Palmaro A, Montastruc JL, et al. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124:3308–3315.
   PubMed Web of Science ®Google Scholar
• Depre F, Aboud N, Mayer B, et al. Efficacy and safety of drugs used in treatment of autoimmune thrombocytopenia: results from one center and one hand. Submitted for publication.
   Google Scholar
• Salama A. Clinically and/or serologically misleading findings surrounding immune haemolytic anaemias. Transfus Med Hemother. 2015;42:311–315.
   PubMed Web of Science ®Google Scholar
• Meyer O, Agaylan A, Bombard S, et al. A novel antigen-specific capture assay for the detection of platelet antibodies and HPA-1a phenotyping. Vox Sang. 2006;91:324–330.
   PubMed Web of Science ®Google Scholar
• Gernsheimer T, McCrae KR. Immune thrombocytopenic purpura in pregnancy. Curr Opin Hematol. 2007;14:574–580.
   PubMed Web of Science ®Google Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995–1008.
   PubMed Web of Science ®Google Scholar
• Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013;98:24–33.
   PubMed Web of Science ®Google Scholar
• Psaila B, Bussel JB. Immune Thrombocytopenia (ITP). 3rd ed. Platelets. Amsterdam:Elsevier Inc; 2013.
   Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–186.
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190–4207.
   PubMed Web of Science ®Google Scholar
• Mahévas M, Gerfaud-Valentin M, Moulis G, et al. Characteristics, outcome and response to therapy of multirefractory chronic immune thrombocytopenia. Blood. 2016;128:1625–1630.
   PubMed Web of Science ®Google Scholar
• Cuker A, Neunert CE. How I treat refractory immune thrombocytopenia. Blood. 2016;128:1547–1554.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:1653–1661.
   PubMed Web of Science ®Google Scholar
• Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015;2:e75–81.
   PubMed Web of Science ®Google Scholar
• Cuker A. Toxicities of the thrombopoietic growth factors. Semin Hematol. 2010;47:289–298.
   PubMed Web of Science ®Google Scholar
• Depre F, Aboud N, Ringel F, et al. Thrombopoietin receptor agonists are often ineffective in immune thrombocytopenia and/or cause adverse reactions: results from one hand. Transfus Med Hemotherapy. 2016;43:375–379.
   PubMed Web of Science ®Google Scholar
• Depre F, Aboud N, Mayer B, et al. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review. submitted for publication. Blood Transfus. 2017 1–6. doi: 10.2450/2017.0258-16. [Epub ahead of print]
   Google Scholar
• Pettigrew M, Garces K, Deuson R, et al. Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. J Med Econ. 2013;16:318–326.
   PubMedGoogle Scholar
• López MF, Mingot ME, Valcárcel D, et al. [Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain]. Med Clin (Barc). 2015;144:389–396.
   PubMed Web of Science ®Google Scholar
• Lee D, Thornton P, Hirst A, et al. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland. Appl Health Econ Health Policy. 2013;11:457–469.
   PubMedGoogle Scholar
• Rodrigo C, Gooneratne L. Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. J Thromb Haemost. 2013;11:1946–1953.
   PubMed Web of Science ®Google Scholar
• Portielje JE, Westendorp RG, Kluin-Nelemans HC, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97:2549–2554.
   PubMed Web of Science ®Google Scholar
• McMillan R, Bussel JB, George JN, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83:150–154.
   PubMed Web of Science ®Google Scholar
• Snyder CF, Mathias SD, Cella D, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin. 2008;24:2767–2776.
   PubMed Web of Science ®Google Scholar
• Saleh MN, Fisher M, Grotzinger KM. Analysis of the impact and burden of illness of adult chronic ITP in the US. Curr Med Res Opin. 2009;25:2961–2969.
   PubMed Web of Science ®Google Scholar
• Neunert CE. Individualized treatment for immune thrombocytopenia: predicting bleeding risk. Semin Hematol. 2013;50(Suppl 1):S55–7.
   PubMedGoogle Scholar
• Cuker A, Cines DB, Neunert CE. Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol. 2016;23:479–485.
   PubMed Web of Science ®Google Scholar
• Cuker A, Cines DB. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2010;2010:377–384.
   PubMed Web of Science ®Google Scholar
• George JN. Sequence of treatments for adults with primary immune thrombocytopenia. Am J Hematol. 2012;87(Suppl 1):S12–5.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F. Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine. Haematologica. 2003;88:1081–1087.
   PubMed Web of Science ®Google Scholar
• Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4:2377–2383.
   PubMed Web of Science ®Google Scholar
• Deuson R, Danese M, Mathias SD, et al. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim. J Med Econ. 2012;15:956–976.
   PubMedGoogle Scholar
• Danese MD, Lindquist K, Gleeson M, et al. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol. 2009;84:631–635.
   PubMed Web of Science ®Google Scholar
• Khellaf M, Le Moine JG, Poitrinal P, et al. Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Ann Hematol. 2011;90:441–446.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Miyakawa Y, Ikeda S, et al. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults. BMC Health Serv Res. 2015;15:2.
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Mathias SD, Snyder CF, et al. Impact of ITP on physician visits and workplace productivity. Curr Med Res Opin. 2010;26:319–328.
   PubMed Web of Science ®Google Scholar
• O’Brien SH, Ritchey AK, Smith KJ. A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). Pediatr Blood Cancer. 2007;48:173–180.
   PubMed Web of Science ®Google Scholar
• Blackhouse G, Xie F, Levine MA, et al. Canadian cost-utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. J Popul Ther Clin Pharmacol. 2012;19:e166–78.
   PubMedGoogle Scholar
• Chatenoud L. Biotherapies targeting T and B cells: from immune suppression to immune tolerance. Curr Opin Pharmacol. 2015;23:92–97.
   PubMed Web of Science ®Google Scholar
• Perry JS, Hsieh CS. Development of T-cell tolerance utilizes both cell-autonomous and cooperative presentation of self-antigen. Immunol Rev. 2016;271:141–155.
   PubMed Web of Science ®Google Scholar
• Abramson J, Husebye ES. Autoimmune regulator and self-tolerance - molecular and clinical aspects. Immunol Rev. 2016;271:127–140.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369–395.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Vignali DA. Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity. 2016;44:1034–1051.
   PubMed Web of Science ®Google Scholar
• Mayer B, Depre F, Ringel F, et al. New aspects on the efficacy of high-dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia. Vox Sang.2017; 112:64–69.
   Google Scholar
• Committee for Medical Products for Human Use (CHMP). Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94033/2007 rev.2). available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004766.pdf, 2010 [ cited November 3, 2014].
   Google Scholar
• Simpson KN, Coughlin CM, Eron J, et al. Idiopathic thrombocytopenia purpura: treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy. Semin Hematol. 1998;35:58–64.
   PubMed Web of Science ®Google Scholar
• Kurata Y, Fujimura K, Kuwana M, et al. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011;93:329–335.
   PubMed Web of Science ®Google Scholar
• Raju TS, Scallon BJ. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem Biophys Res Commun. 2006;341:797–803.
   PubMed Web of Science ®Google Scholar
• Ritamo I, Cloutier M, Valmu L, et al. Comparison of the glycosylation of in vitro generated polyclonal human IgG and therapeutic immunoglobulins. Mol Immunol. 2014;57:255–262.
   PubMed Web of Science ®Google Scholar
• Fokkink WJ, Falck D, Santbergen TC, et al. Comparison of Fc N-Glycosylation of pharmaceutical products of intravenous immunoglobulin G. Plos One. 2015;10:e0139828.
   PubMed Web of Science ®Google Scholar
• Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica. 1993;78:35–40.
   PubMedGoogle Scholar
• Bussel JB, Eldor A, Kelton JG, et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost. 2004;91:771–778.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670–673.
   PubMed Web of Science ®Google Scholar
• Zuercher AW, Spirig R, Baz Morelli A, et al. IVIG in autoimmune disease - Potential next generation biologics. Autoimmun Rev. 2016;15:781–785.
   PubMed Web of Science ®Google Scholar
• Salama A, Mueller-Eckhardt C. Use of Rh antibodies in the treatment of autoimmune thrombocytopenia. Transfus Med Rev. 1992;6:17–25.
   PubMedGoogle Scholar
• Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89:2689–2700.
   PubMed Web of Science ®Google Scholar
• Newman GC, Novoa MV, Fodero EM, et al. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol. 2001;112:1076–1078.
   PubMed Web of Science ®Google Scholar
• Cooper N, Woloski BM, Fodero EM, et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood. 2002;99:1922–1927.
   PubMed Web of Science ®Google Scholar
• George JN, Raskob GE, Vesely SK, et al. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol. 2003;74:161–169.
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Young G, Bertolone SJ, et al. Single dose of anti-D immune globulin at 75 micro g/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr. 2006;148:489–494.
   PubMed Web of Science ®Google Scholar
• Gaines AR, Lee-Stroka H, Byrne K, et al. Investigation of whether the acute hemolysis associated with Rh(o)(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model. Transfusion. 2009;49:1050–1058.
   PubMed Web of Science ®Google Scholar
• Meyer O, Kiesewetter H, Hermsen M, et al. Efficacy and safety of anti-D given by subcutaneous injection to patients with autoimmune thrombocytopenia. Eur J Haematol. 2004;73:71–72.
   PubMed Web of Science ®Google Scholar
• Kjaersgaard M, Edslev PW, Hasle H. Subcutaneous anti-D treatment of idiopathic thrombocytopenic purpura in children. Pediatr Blood Cancer. 2009;53:1315–1317.
   PubMed Web of Science ®Google Scholar
• Trebo MM, Frey E, Gadner H, et al. Subcutaneous anti-D globulin application is a safe treatment option of immune thrombocytopenia in children. Ann Hematol. 2010;89:415–418.
   PubMed Web of Science ®Google Scholar
• Easdale S, Stasi R. Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia. Expert Opin Biol Ther. 2013;13:1085–1092.
   PubMed Web of Science ®Google Scholar
• Robak T, Windyga J, Trelinski J, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood. 2012;120:3670–3676.
   PubMed Web of Science ®Google Scholar
• Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25–33.
   PubMed Web of Science ®Google Scholar
• Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119:5989–5995.
   PubMed Web of Science ®Google Scholar
• Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115:2755–2762.
   PubMed Web of Science ®Google Scholar
• Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs. dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013;121:1976–1981.
   PubMed Web of Science ®Google Scholar
• Okazuka K, Masuko M, Matsuo Y, et al. Successful treatment of severe newly diagnosed immune thrombocytopenia involving an alveolar hemorrhage with combination therapy consisting of romiplostim, rituximab and vincristine. Intern Med. 2013;52:1239–1242.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Rossi EA, Stein R, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009;113:1062–1070.
   PubMed Web of Science ®Google Scholar
• Liebman HA, Saleh MN, Bussel JB, et al. Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. Br J Haematol. 2013;162:693–701.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol. 2010;28:3525–3530.
   PubMed Web of Science ®Google Scholar
• Van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol. 2010;47:199–210.
   PubMed Web of Science ®Google Scholar
• Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2007;136:309–314.
   PubMed Web of Science ®Google Scholar
• Jordan NP, D’Cruz DP. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus. Expert Opin Drug Metab Toxicol. 2015;11:1635–1645.
   PubMed Web of Science ®Google Scholar
• Frampton JE, Wagstaff AJ.Alemtuzumab. Drugs. 2003;63:1229–1243. discussion 45-6.
   PubMed Web of Science ®Google Scholar
• Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011;118:6299–6305.
   PubMed Web of Science ®Google Scholar
• Moulis G, Lapeyre-Mestre M, Montastruc JL, et al. Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. Autoimmun Rev. 2015;14:168–173.
   PubMed Web of Science ®Google Scholar
• Basciano PA, Bussel JB. Thrombopoietin-receptor agonists. Curr Opin Hematol. 2012;19:392–398.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Palmaro A, Montastruc F, et al. Signal for thrombosis with eltrombopag and romiplostim: a disproportionality analysis of spontaneous reports within vigibase®. Drug Saf. 2015;38:1179–1186.
   PubMed Web of Science ®Google Scholar
• Mahévas M, Fain O, Ebbo M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014;165:865–869.
   PubMed Web of Science ®Google Scholar
• González-López TJ, Sánchez-González B, Pascual C, et al. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia. Platelets. 2015;26:83–86.
   PubMed Web of Science ®Google Scholar
• Carpenedo M, Cantoni S, Coccini V, et al. Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice. Hematol Rep. 2015;7:5673.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Ruggeri M. Is splenectomy still the gold standard for the treatment of chronic ITP? Am J Hematol. 2008;83:91.
   PubMed Web of Science ®Google Scholar
• Michel M, Suzan F, Adoue D, et al. Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012. Br J Haematol. 2015;170:218–222.
   PubMed Web of Science ®Google Scholar
• Moulis G, Sailler L, Sommet A, et al. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. Am J Hematol. 2014;89:41–46.
   PubMed Web of Science ®Google Scholar
• Clarkson SB, Bussel JB, Kimberly RP, et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med. 1986;314:1236–1239.
   PubMed Web of Science ®Google Scholar
• Yu X, Menard M, Prechl J, et al. Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity. Blood. 2016;127:132–138.
   PubMed Web of Science ®Google Scholar
• Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009;113:3154–3160.
   PubMed Web of Science ®Google Scholar
• Neschadim A, Kotra LP, Branch DR. Small molecule phagocytosis inhibitors for immune cytopenias. Autoimmun Rev. 2016;15:843–847.
   PubMed Web of Science ®Google Scholar
• Davis JC, Totoritis MC, Rosenberg J, et al. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:95–101.
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JC, Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:3251–3258.
   PubMed Web of Science ®Google Scholar
• Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol. 2008;141:545–548.
   PubMed Web of Science ®Google Scholar
• Termeer C, Averbeck M, Hara H, et al. Targeting dendritic cells with CD44 monoclonal antibodies selectively inhibits the proliferation of naive CD4+ T-helper cells by induction of FAS-independent T-cell apoptosis. Immunology. 2003;109:32–40.
   PubMed Web of Science ®Google Scholar
• Crow AR, Song S, Suppa SJ, et al. Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP? Blood. 2011;117:971–974.
   PubMed Web of Science ®Google Scholar
• Amash A, Wang L, Wang Y, et al. CD44 antibody inhibition of macrophage phagocytosis targets fcγ receptor- and complement receptor 3-dependent mechanisms. J Immunol. 2016;196:3331–3340.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Nomura S, Fujimura K, et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood. 2004;103:1229–1236.
   PubMed Web of Science ®Google Scholar
• Pinelli DF, Ford ML. Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance. Immunotherapy. 2015;7:399–410.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Peng J, Sun JZ, et al. Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura. J Thromb Haemost. 2008;6:158–165.
   PubMed Web of Science ®Google Scholar
• Romano A, Conticello C, Di Raimondo F. Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy. 2013;5:327–352.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Rupolo M, Michieli M, et al. Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus. Rheumatology (Oxford). 2014;53:381–382.
   PubMed Web of Science ®Google Scholar
• Fröhlich K, Holle JU, Aries PM, et al. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis. 2011;70:1344–1345.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Hoffman R. Cytokines for the treatment of thrombocytopenia. Semin Hematol. 2007;44:166–182.
   PubMed Web of Science ®Google Scholar
• Fogarty PF, Seggewiss R, McCloskey DJ, et al. Anti-interleukin-2 receptor antibody (daclizumab) treatment of corticosteroid-refractory autoimmune thrombocytopenic purpura. Haematologica. 2006;91:277–278.
   PubMed Web of Science ®Google Scholar
• Salama A, Bhakdi S, Mueller-Eckhardt C, et al. Deposition of the terminal C5b-9 complement complex on erythrocytes by human red cell autoantibodies. Br J Haematol. 1983;55:161–169.
   PubMed Web of Science ®Google Scholar
• Najaoui A, Bakchoul T, Stoy J, et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol. 2012;88:167–174.
   PubMed Web of Science ®Google Scholar
• Salama A. Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review. Transfus Med Hemother. 2015;42:294–301.
   PubMed Web of Science ®Google Scholar
• Berentsen S. Role of complement in autoimmune hemolytic anemia. Transfus Med Hemother. 2015;42:303–310.
   PubMed Web of Science ®Google Scholar
• Northrup L, Christopher MA, Sullivan BP, et al. Combining antigen and immunomodulators: emerging trends in antigen-specific immunotherapy for autoimmunity. Adv Drug Deliv Rev. 2016;98:86–98.
   PubMed Web of Science ®Google Scholar
• Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199:1455–1465.
   PubMed Web of Science ®Google Scholar
• Scalapino KJ, Tang Q, Bluestone JA, et al. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol. 2006;177:1451–1459.
   PubMed Web of Science ®Google Scholar
• Lapierre P, Béland K, Yang R, et al. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology. 2013;57:217–227.
   PubMed Web of Science ®Google Scholar
• Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin Immunol. 2014;153:23–30.
   PubMed Web of Science ®Google Scholar
• Gitelman SE, Bluestone JA. Regulatory T cell therapy for type 1 diabetes: may the force be with you. J Autoimmun. 2016;71:78–87.
   PubMed Web of Science ®Google Scholar
• König M, Rharbaoui F, Aigner S, et al. Tregalizumab - A monoclonal antibody to target regulatory t cells. Front Immunol. 2016;7:11.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Isenberg DA, Wallace DJ. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. Lupus Sci Med. 2015;2:e000104.
   PubMed Web of Science ®Google Scholar
• Van Brussel I, Lee WP, Rombouts M, et al. Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality? Autoimmun Rev. 2014;13:138–150.
   PubMed Web of Science ®Google Scholar
• Raïch-Regué D, Glancy M, Thomson AW. Regulatory dendritic cell therapy: from rodents to clinical application. Immunol Lett. 2014;161:216–221.
   PubMed Web of Science ®Google Scholar
• Llanos C, Mackern-Oberti JP, Vega F, et al. Tolerogenic dendritic cells as a therapy for treating lupus. Clin Immunol. 2013;148:237–245.
   PubMed Web of Science ®Google Scholar
• Kontos S, Grimm AJ, Hubbell JA. Engineering antigen-specific immunological tolerance. Curr Opin Immunol. 2015;35:80–88.
   PubMed Web of Science ®Google Scholar
• Suwandi JS, Toes RE, Nikolic T, et al. Inducing tissue specific tolerance in autoimmune disease with tolerogenic dendritic cells. Clin Exp Rheumatol. 2015;33:S97–103.
   PubMed Web of Science ®Google Scholar
• Patel DA, Puig-Canto A, Challa DK, et al. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J Immunol. 2011;187:1015–1022.
   PubMed Web of Science ®Google Scholar
• Martins JP, Kennedy PJ, Santos HA, et al. A comprehensive review of the neonatal Fc receptor and its application in drug delivery. Pharmacol Ther. 2016;161:22–39.
   PubMed Web of Science ®Google Scholar
• Bernton E, Gannon W, Kramer W, et al. PRTX-100 and methotrexate in patients with active rheumatoid arthritis: a Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study. Clin Pharmacol Drug Dev. 2014;3:477–486.
   PubMed Web of Science ®Google Scholar